SCHEMBL5847486

SCHEMBL5847486

COc1ccc(-c2ncccc2C)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.44
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
SMO Q99835 7/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
CDC7 O00311 2/20 0.41
DBF4 Q9UBU7 2/20 0.41
CCNT1 O60563 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
CDK9 P50750 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
CYP3A4 P08684 2/20 0.40
CYP17A1 P05093 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17178285 0.81 HSP90AA1 (0.46) PIK3CDHSP90AA1HSP90AB1ALDH1A1KDM4E
SCHEMBL5847190 0.81 L3MBTL1 (0.48) SMOALDH1A1HPGDMAPTRAB9A
SCHEMBL20595575 0.80 HSP90AA1 (0.44) HSP90AA1HSP90AB1CYP3A4CYP17A1CYP11B1
SCHEMBL29979351 0.78 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDCYP3A4CYP11B1
SCHEMBL1207550 0.75 DPP4 (0.57) SMOALDH1A1PDE2A
SCHEMBL17751232 0.75 HSP90AA1 (0.52) HSP90AA1HSP90AB1ALDH1A1CYP3A4MAPT
SCHEMBL20595681 0.75 CRHR1 (0.44) HSP90AA1HSP90AB1ALDH1A1KDM4EHPGD
SCHEMBL12325069 0.74 HSP90AA1 (0.56) HSP90AA1HSP90AB1ALDH1A1KDM4EHPGD
SCHEMBL935169 0.74 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A
SCHEMBL20595679 0.74 HSP90AA1 (0.45) HSP90AA1HSP90AB1CDC7DBF4CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151109-B2 Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY LLC (US) 2006-12-19 US disclosed
EP-1485384-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS Pharmacia & Upjohn Company LLC (US) 2004-12-15 EP disclosed
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY 2004-01-01 US disclosed
WO-2003078435-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS PHARMACIA & UPJOHN COMPANY LLC (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators CRHR1, HTR5A, CRH PIK3CD 2090/4885HSP90AA1 3290/4885HSP90AB1 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.